Viewing data from:

NATEGLINIDE

ANDA

NATEGLINIDE | A205544 | RISING PHARMA HOLDINGS INC

2 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 2 NDCs

Highest NADAC/Unit

$0.2411

per ea

Lowest NADAC/Unit

$0.1996

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
16571075909NATEGLINIDE 120 MG TABLET	$0.2411	EA	Generic	—	2026-06-17
16571075809NATEGLINIDE 60 MG TABLET	$0.1996	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain8 active DMFs2 inactive

7 active API suppliers hold Drug Master Files for this ingredient.

DR REDDYS LABORATORIES LTDNATEGLINIDE (PREMIX)

DMF 178472004

TAPI NL BVNATEGLINIDE

DMF 179102004

SYNTHIMED LABS PRIVATE LTDNATEGLINIDE USP

DMF 202312007

UNICHEM LABORATORIES LTDNATEGLINIDE

DMF 214842008

CADILA PHARMACEUTICALS LTDNATEGLINIDE FORM H USP

DMF 265182013

USV PRIVATE LTDNATEGLINIDE USP [MICRONISED]

DMF 268822013

UNICHEM LABORATORIES LTDNATEGLINIDE (FORM-H) USP

DMF 289342015

ZYDUS LIFESCIENCES LTDNATEGLINIDE USP

DMF 375012022

CIPLA LTDInactiveNATEGLINIDE USP

DMF 179062004

CADILA PHARMACEUTICALS LTDInactiveNATEGLINIDE FORM B

DMF 219622008

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — 60MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Jun 18, 2018

No patent or exclusivity listings for this strength.

#002 — 120MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jun 18, 2018